MeiraGTx Holdings (FRA:328) Total Current Liabilities: €152.35 Mil (As of Mar. 2026)


FRA:328 MeiraGTx Holdings PLC FRA:328
55 GF Score
Price €12.00
GF Value €20.58
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MeiraGTx Holdings Total Current Liabilities?

MeiraGTx Holdings FRA:328 +8.11% 55 Total Current Liabilities is €152.35 Mil as of Mar. 2026. GuruFocus rates FRA:328 with a GF Score™ of 55/100 and a GF Value™ of €20.58 (Possible Value Trap). The stock has 5 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. MeiraGTx Holdings's total current liabilities for the quarter that ended in Mar. 2026 was €152.35

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

MeiraGTx Holdings Total Current Liabilities Related Terms

MeiraGTx Holdings Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for MeiraGTx Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeiraGTx Holdings Total Current Liabilities Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.29 77.48 61.51 58.05 104.66

MeiraGTx Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.44 46.33 130.29 104.66 152.35
FRA:328
55GF Score
MeiraGTx Holdings PLC FRA:328
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeiraGTx Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

MeiraGTx Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=25.747+23.517
+Other Current Liabilities+Current Deferred Liabilities
=53.881+1.517
=104.66

MeiraGTx Holdings's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=27.065+23.464
+Other Current Liabilities+Current Deferred Liabilities
=100.094+1.727
=152.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of €152.35 Mil mean?
MeiraGTx Holdings (FRA:328) has a Total Current Liabilities of €152.35 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for MeiraGTx Holdings and its competitors.
Is MeiraGTx Holdings' Total Current Liabilities too high?
MeiraGTx Holdings' current Total Current Liabilities is €152.35 Mil. Overall, MeiraGTx Holdings has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Total Current Liabilities compare to XNCR and WVE?
MeiraGTx Holdings' Total Current Liabilities of €152.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current Total Current Liabilities is €152.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €20.58, compared to a current price of €12.00 — trading 41.7% below its estimated fair value. The current Total Current Liabilities is €152.35 Mil. MeiraGTx Holdings' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current Total Current Liabilities is €152.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?

Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued. The current stock price of €12.00 is trading 41.7% below its estimated GF Value™ of €20.58. GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.

Key valuation signals for FRA:328:

  • Total Current Liabilities: €152.35 Mil
  • GF Value™: €20.58 vs. price of €12.00 (41.7% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeiraGTx Holdings Business Description

Other Exchanges MGTX:USA328:Germany
Address 655 Third Avenue, Suite 1115, New York, NY, USA, 10017
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
55GF Score

Get the complete analysis for FRA:328

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.00
Price
€20.58
GF Value